Impact of postmenopausal hormone therapy on cardiovascular events and cancer

BMJ

Volumn 315, Issue 7109, 1997, Pages 676-

  Singleton, Stephen ^a   Bailey, Kathryn ^a   Shah, Sunil ^b   Rhodes, Leonaura ^b   Seagroatt, Valerie ^c   Sundkvist, Torbjorn ^d   al Azzawi, Farook ^e   Thompson, John ^e   Halligan, Aidan ^e   Col, Nananda F ^f   Wong, John B ^f   Pauker, Stephen G ^f   Karas, Richard ^f   Hemminki, Elina ^g  

^a Northumberland Health Authority   (United Kingdom)

^b Surrey Communicable Disease Control Service   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Brent and Harrow Health Authority   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f TUFTS MEDICAL CENTER   (United States)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MESTRANOL;

CANCER; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DRUG CONTRAINDICATION; DRUG MEGADOSE; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; LETTER; META ANALYSIS; METHODOLOGY; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK; STATISTICAL ANALYSIS; STROKE; THROMBOEMBOLISM; CLINICAL TRIAL (TOPIC); EPIDEMIOLOGY; ESTROGEN THERAPY; NOTE; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; ODDS RATIO; TREATMENT OUTCOME;

EID: 0030964629     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.315.7109.676     Document Type: Letter

References (23)

1. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53. (19 July.)
2. Spector T, Thompson S. The potential and limitations of meta-analysis. J Epidemiol Community Health 1991; 45: 89–92.
3. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Josse M, et al. Postmenopausal hormone therapy and mortality. NEngl J Med 1997; 336: 1769–1775.
4. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl JMed 1988; 318: 1728–1733.
5. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53. (19 July.)
6. Dickersin K, Scherer R, Lefebvre C. Identifyingrelevant studies for systematic reviews. BMJ 1994; 309: 1286–1291.
7. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53. (19 July.)
8. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–1037.
9. Speroff L, Rowan J, Symons J, Genant H, Wilbom W. Thecomparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996; 276: 1397–1403.
10. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995; 273: 199-208.
11. Egger M, Davey-Smith G. Misleading meta-analysis. BMJ 1995; 310: 752–754.
12. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53. (19 July.)
13. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–980.
14. Writing Group for the PEPI Trial. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995; 273: 199–208.
15. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–461.
16. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53. (19 July.)
17. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044–1049.
18. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988; 297: 519–522.
19. Ross RK, Paganini-Hill A, Mack TM, Henderson BE. Cardiovascular benefits of estrogen replacement therapy. Am J ObstetGynecol 1989; 160: 1301–1306.
20. Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. BMJ. 1973: 3, 515.
21. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53. (19 July.)
22. Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. BMJ. 1973: 3, 515.
23. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–1037.